Cyted Health today announces the appointment of Chris Freeman as a Strategic Advisor to the company, where he will advise on Cyted Health’s growth and US commercialization.
Chris Freeman holds extensive experience in the delivery of successful commercialization strategies across the healthcare sector. As Chief Commercial Officer of Guardant Health, a Nasdaq-listed leading precision oncology company, Chris leads the company’s commercial function, which include multiple diagnostic tests across the cancer care continuum from early detection to post-treatment monitoring. Previously, Chris worked for ten years at Gilead Sciences, a biopharma company, where he served as Vice President of its $13 billion HIV treatment and prevention business, Elan Pharmaceuticals, and Genentech, where he spearheaded the marketing of its flagship oncology products.
“The expertise Chris Freeman brings in leading large-scale commercialization strategies is unparalleled,” said Dr Marcel Gehrung, Cyted Health’s CEO and Co-Founder. “Cyted Health’s transformative technology is already modernising diagnostic pathways across the UK. Chris’ insights will be instrumental as we pursue significant opportunities ahead of us in the US and globally.”
“I am delighted to contribute my experience in healthcare leadership to Cyted Health as it builds its presence in the US,” said Chris Freeman. “EndoSign® and the accompanying molecular test are game-changing tools for the detection and monitoring of upper gastrointestinal conditions. It has vast potential in the US, and I am excited to be a part of this growth story”.
Chris’s appointment marks the next step in Cyted Health’s work in the US following the appointment of Betsy Hanna as US President and FDA clearance for Cyted Health’s EndoSign® device in 2024.
